Spotlight Innovation Inc. (fka STLT)

[bow-tie]

Other Study on CB24 And VRCTC-310: VRCTC-310 is a natural product produced by combining two purified snake venom, a non-covalent heterodimer crotoxinn, and a basic amphipathic peptide cardiotoxin. A phase I study was performed to evaluate the mechanism tolerated dose (MTD), safety profile, and pharmacokinetic data with VRCTC-310. 15 patients with refractory malignancies were given intramuscular injection daily for 30 days continuously. MTD was found to 0.017 mg/kg and recommended for phase II studies with dose range of 0.017 mg/kg (Costa et al., 1997).

According to a news published in a journal (Popular science), an Irish company is using American rattle snake venom to test its anti-cancer potential. They isolated a protein from rattle snake venom that causes malignant cancer cell to commit suicide. This company has developed a venom-derived drug called CB24 and started testing it on humans in October’11. That drug has already been tested in mice and human cell lines with great success.

http://perihalbarah.blogspot.com/2013/04/snake-venom-as-anticancer-agent.html